Analysts Offer Predictions for Arcellx FY2025 Earnings

Arcellx, Inc. (NASDAQ:ACLX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Arcellx in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings per share of ($2.54) for the year. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share.

ACLX has been the topic of several other reports. Bank of America upped their price target on shares of Arcellx from $84.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Stifel Nicolaus upped their target price on Arcellx from $83.00 to $122.00 and gave the company a “buy” rating in a research note on Friday, October 18th. UBS Group raised their price target on Arcellx from $106.00 to $114.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Truist Financial upped their price objective on Arcellx from $87.00 to $136.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $115.00 target price on shares of Arcellx in a research report on Tuesday, December 10th. Thirteen research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $105.93.

Arcellx Trading Up 0.1 %

Shares of ACLX opened at $66.57 on Wednesday. The company’s fifty day simple moving average is $81.36 and its 200-day simple moving average is $76.51. The company has a market cap of $3.60 billion, a P/E ratio of -93.76 and a beta of 0.33. Arcellx has a twelve month low of $47.88 and a twelve month high of $107.37.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.06. The company had revenue of $26.03 million during the quarter, compared to the consensus estimate of $35.21 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%.

Insider Activity

In related news, Director Kavita Patel sold 33,763 shares of Arcellx stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $104.14, for a total transaction of $3,516,078.82. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Heery sold 3,301 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $79.55, for a total value of $262,594.55. Following the sale, the insider now owns 35,517 shares of the company’s stock, valued at approximately $2,825,377.35. This represents a 8.50 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,416 shares of company stock worth $6,242,800. 6.24% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcellx

A number of large investors have recently added to or reduced their stakes in the company. First Turn Management LLC purchased a new position in shares of Arcellx in the 3rd quarter worth approximately $17,896,000. Charles Schwab Investment Management Inc. lifted its position in Arcellx by 4.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,093 shares of the company’s stock valued at $27,399,000 after acquiring an additional 14,200 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Arcellx by 37.0% in the third quarter. Harbor Capital Advisors Inc. now owns 27,896 shares of the company’s stock valued at $2,330,000 after acquiring an additional 7,534 shares in the last quarter. Lord Abbett & CO. LLC grew its holdings in Arcellx by 2.1% in the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company’s stock worth $74,478,000 after purchasing an additional 18,004 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Arcellx during the third quarter worth $800,000. 96.03% of the stock is currently owned by institutional investors.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).